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ABSTRACT
Surgical gloves provide a protective blockade for patients and members of the surgical team. Glove integrity is critical
in an era of blood-borne pathogens. Therefore, the need for improved means for prevention and also gloving and appropriate
hand hygiene in a hospital setting is ostensible. This perspective highlights the progress on antimicrobial surgical gloves in
deducting the microbial passage after a glove puncture in a model of wound contamination. Moreover, traditional methods to
avoid microbes in the hospital and various antimicrobial agents, such as metal ions and antiseptic dyes, are reviewed.
[doi:10.5254/rct.15.84882]
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I. INTRODUCTION
A. SURGICAL GLOVES
Blood, exposing the nature of the surgery, increases the risk of microbe transfer through
contact between surgical patients and the surgical team. The transferred microbes may cause
postoperative infections in patients or even blood-borne infections in both patients and the
surgical team. Therefore, protecting both patients and the surgical team and decreasing the risk
of microbial transfer is the center of interest. The application of protective barriers (e.g., surgical
gloves) is a possible way to decrease contamination risk.1–5 The risk of surgical site infections
(SSIs) depends on factors related to the patient, surgical team, and surgical intervention but is
ultimately related to the possibility of surgical wound contamination during surgery.6,7 Using
surgical gloves is an essential part of SSI prevention, as gloves provide a physical barrier to
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microorganisms present on the hands of health care workers (HCWs), in the environment, and
on patients.8,9 In addition, pathogen transmission by contaminated gloves has been recognized
as an important vector for the pathogenesis of health care–associated infections.10,11 Surgical
gloves are complementary to and of equal importance as surgical hand antisepsis12; however,
their use does not guarantee total safety for the patient or the surgical team, because of
inevitable microperforations or tears.13,14 Gloves act as barriers to microorganisms but do not
eliminate them.15 Rather, they create a moist environment, promoting and exacerbating the
proliferation of microorganisms, especially when surgical antisepsis of the hands is performed
insufficiently or inappropriately or is not performed at all.16–18 Thus, glove perforation
facilitates the transfer of pathogens through the holes (even microscopic), increasing the risk of
surgical site contamination, which, based on the volume, virulence, and host resistance, could
directly leads to an SSI.19 Surgical gloves are usually used as a protective barrier against
contamination, such as bacteria and viruses.20,21 Therefore, these gloves should be designed to
be entirely impermeable to the contaminants or microorganisms during application. This study
suggests that applying antibacterial gloves can reduce bacterial transfer through surgical
gloves.1
B. DIFFERENT MICROBES IN HOSPITALS
The health care unit is an environment that is constantly exposed to myriad microbial
pathogens. In 2010, more than 69 475 cases of health care–associated infections and 81 139
pathogens were reported in the United States.22 The pathogens varied by type of health care–
associated infection (HAI; Table I), but overall, 80% of the reported pathogens were composed of
Staphylococcus aureus (16%), Enterococcus spp. (14%), Escherichia coli (12%), coagulase-
negative staphylococci (11%), Candida spp. (9%), Klebsiella pneumoniae (and Klebsiella
oxytoca; 8%), Pseudomonas aeruginosa (8%), and Enterobacter spp. (5%). Patients themselves
are hosts of a variety of endogenous microorganisms (Table I) and may inoculate themselves with
pathogens or spread them to other individuals and surroundings.23
Previous studies have shown that HCWs’ gloves might contaminate through direct and indirect
contact with colonized patients or the patients’ environment, which, alongside inadequate hand
hygiene, would lead to HAIs.24–26 Dramatic microbial multidrug resistance related to an increase in
health care infections, such as methicillin-resistant S. aureus (MRSA) and vancomycin-resistant
enterococci (VRE), has created a demand for a new alternative prevention material.27,28 The
application of antimicrobial gloves in all health care units (e.g., operating theatres, wards, clinics)
will help to reduce the possibility of microbes’ horizontal spread and prevent HAIs.
II. TRADITIONAL METHODS TO AVOID MICROBES IN THE HOSPITAL
A. DOUBLE GLOVING
To reduce the risk of bacterial transmission and provide further barrier, wearing two sets of
gloves or cloth outer gloves has been suggested.29,30 Double gloving is wearing two pairs of
surgical gloves to decrease the risk of contamination origin from glove failure or penetration of the
gloves by sharp objects during medical procedures.1,31 Double gloving provides significant
protection against inner glove perforation during surgical procedures as compared with a single-
glove layer.32 However, there are several reasons for not double gloving; the most cited reason by
surgeons and residents is a decrease in manual dexterity and comfort. Another reason for not double
gloving is adaptation time, which can vary from 1 to 120 days, according to Patterson et al.3
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B. HAND WASHING
HCWs’ hands could contaminate with bacteria in contact with the skin of hospitalized patients
by touching inanimate objects in patient rooms or during cleaning procedures.33–36 Furthermore,
feeding, changing diapers, playing, and even contact with surfaces contaminated by secretions of
infants infected with respiratory syncytial virus might contaminate HCWs. Furthermore, bacteria
on the hands of surgeons might cause wound infections if introduced into the operative field during
surgery,37 followed by rapid bacteria multiplication under surgical gloves if hands are washed with
a nonantimicrobial soap.
Although hand washing appears to be a good method for controlling bacterial contamination
among HCWs, frequent hand antisepsis using alcohol-based formulations leads to skin dryness.36
III. TRADITIONAL ANTIMICROBIAL AGENTS FOR GLOVES
The toxicity of the antibacterial agent and its degradation products in the human body should be
assessed by the manufacturers.38
Triclosan (2, 4, 40-trichloro-2 0-hydroxydiphenyl ether; TCS) is a broad-spectrum antibacterial
agent usually used in various personal care products.39,40 Unfortunately, there is some evidence that
proves the toxicity of TCS to humans and environments.41,42 This evidence strongly demonstrates
TCS toxicity to aquatic species such as algae, invertebrates, and certain types of fish. Although it is
highly toxic to algae and exerts reproductive and developmental effects in some fishes,41 some
studies reveal TCS’s potential for endocrine disruption, thyroid hormone disruption, and possibly
reproductive axis problems.41,43
IV. ANTIMICROBIAL AGENTS FOR SURGICAL GLOVES
It is extremely important to search for new materials to use in biomedical applications.44,45
Antibiotic resistance has prompted the search for new agents that can inhibit bacterial growth.
Researchers have found that graphene-based nanomaterials possess excellent antibacterial
properties.46 Although antibacterial materials are widely used in daily life, and the antibacterial
properties of nanomaterials are increasingly being explored and developed as commercial products,
their cytotoxicity and biocompatibility have raised questions and concerns.
As a result of the extremely thin nature of surgical gloves and the possibility of puncturing or
rupturing during use, the risk of contamination seems to be tragically high. Suitable antibacterial
agents include biguanides such as chlorhexidine salts (e.g., gluconate salt [CHG]) and
polyhexamethyl biguanide (PHMB), quaternary ammonium salts such as benzalkonium chloride
and benzethonium chloride, chlorinated phenols such as triclosan, essential oils such as farnesol,
phenoxyethanol, octoxyglycerin, iodine compounds, silver salts, antifungal agents, and the like.20
A polymer blend films of polyvinyl alcohol and natural rubber blends show good antibacterial
activity against S. aureus, E. coli, and Acinetobacter baumannii.47
An antibacterial medical glove consists essentially of an outer elastomeric body in the shape of
a hand and an inner coating containing an antimicrobial agent, with the inner coating being capable
of slowly releasing an antimicrobial agent in an amount and over a period of time sufficient to
maintain an essentially bacteria-free and fungus-free environment within the glove after the glove
has been donned.48 Aik et al.49 coated the inner layer of a surgical glove with the cationic
antibacterial agents CHG or PHMB. In this patent, cornstarch was applied as an antiblocking agent
to immobilize the CHG and PHMB in place and control the slow secretion of CHG and PHMB
during surgical glove application.20 Figure 1 is an example of applying an antimicrobial material in
a surgical glove.
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A. METAL ION PARTICLES
1. Silver ion particles. — It has been known for a long time that ionic silver is a common
antibacterial metal oxide against the pathogens including E. coli.50,51 It is believed that silver
particles bind into bacterial DNA content and prevent cell replication and interruption and
inactivation of the electron transport chain of metabolic enzymes by binding to their sulfhydryl
group,52,53 according to Figure 2.
In the study by Li et al.,55 the silver nanoparticles’ antibacterial activity inE. coliwas explored
and revealed that 10 lg/mL of the silver nanoparticles completely inhibit the growth of 107 cfu/mL
E. coli cells in liquid Mueller–Hinton medium.
The presence of silver nanoparticles at a concentration of 10lgcm3 preventsE. coli growth by
70%, whereas it is significantly reduced on plates with a concentration of 20 lgcm3.56,57 A
concentration of 50–60 lgcm3 caused 100% inhibition of bacterial growth (Figure 3). As
expected, the inhibition of bacterial growth depends on the number of cells applied in the test.58–60
2. Copper Ion Particles. — Copper has been recognized as having the potential for
antibacterial activity.61,62 Copper shows bactericidal activity against a range of bacteria including
E. coli, MRSA, Listeria monocytogenes, Clostridium difficile, yeasts, and viruses.63–66 Casey et
TABLE I
BACTERIA COMMONLY FOUND ON THE SURFACES OF THE HUMAN BODY23
Bacterium Skin Conjunctiva Nose Pharynx Mouth
Lower
GI
Ant.
urethra Vagina
S. epidermidis þþ þ þþ þþ þþ þ þþ þþ
S. aureusa þ þ/ þ þ þ þþ þ/ þ
S. mitis þ þþ þ/ þ þ
S. salivarius þþ þþ
S. mutansa þ þþ
E. faecalisa þ/- þ þþ þ þ
S. pneumoniaea þ/ þ/ þ þ þ/
S. pyogenesa þ/ þ/ þ þ þ/- þ/
Neisseria sp. þ þ þþ þ þ þ
N. meningitidisa þ þþ þ þ
Enterobacteriaceaea þ/ þ/ þ/ þ þþ þ þ
Proteus sp. þ/ þ þ þ þ þ þ
P. aeruginosaa þ/ þ/ þ þ/
H. influenzaea þ/ þ þ þ
Bacteroides sp.a þþ þ þ/
B. bifidum þþ
Lactobacillus sp. þ þþ þþ þþ
Clostridium sp. þ/ þþ
Clostridium tetani þ/-
Corynebacteria þþ þ þþ þ þ þ þ þ
Mycobacteria þ þ/ þ/ þ þ
Actinomycetes þ þ
Spirochetes þ þþ þþ
Mycoplasmas þ þ þ þ/ þ
a Potential pathogen.þþ¼nearly 100%;þ¼ common (about 25%);þ/¼ rare (<5%).
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al.61 reported that copper-containing surfaces continuously reduce environmental microbial
contamination. It has been shown that copper is strongly antibacterial against MRSA, EMRSA-1,
and EMRSA-16, preventing their long-term persistence.63 Copper alley bactericidal activity varies
from 30 s (against Saccharomyces cerevisiae)67 to 576 h (against Aspergillus niger wet spores).68 In
another study, a copper-coated respiratory face mask showed significant biocidal activity against
influenza virus.69
B. ANTISEPTIC DYES AND SALTS
1. Gardine. — Gardine is an innovative antiseptic dye with broad-spectrum antibacterial
effects prepared by combining brilliant green and chlorhexidine.24,70 Although brilliant green and
chlorhexidine have low antibacterial activity when applied separately, using their combination
revealed enormous antibacterial activity due to the synergistic effect of their mixture.71,72 The
safety of gardine solution for human use was granted. For instant, brilliant green commonly has
been applied in skin lesions as an anti-infective agent.73 Daily application of low-concentration
chlorhexidine proves to be nontoxic, and it is widely used in mouthwash solutions along with other
antiseptics.74 Even though the noncytotxicity of brilliant green and chlorhexidine has been
demonstrated, more studies should be performed to test the cytotoxicity of the gardine.
Gardine-treated bacteria cultures show significant reduction within 30 s for all tested
organisms including MRSA,75 VRE, E. coli,Acinetobacter, and Candida albicans.76,77 Complete
kill was achieved within 30 s for MRSA and E. coli, 10 min for Acinetobacter, and 30 min for C.
albicans.24 Another study performed by Paul et al.71 confirmed that gendine-coated stainless
provided significant baseline antimicrobial efficacy against MRSA for long durability of 2 weeks.
Antiseptic dyes interfere with cell-cell communication, which inhibits bacteria aggregation and
creation of biofilm and finally leads to lysis of the bacteria membrane.78
FIG. 1. — (A) Microscopic picture of trilayer surgical glove showing middle layer containing droplike mixture of
chlorhexidine and quaternary ammonium salts. (B) Artist rendition of trilayer surgical glove demonstrating inner (I) and
outer (O) surfaces adjacent.1,2
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FIG. 2. — Silver particles bind into bacterial DNA content and prevent cell replication and interrupting and inactivating the
electron transport chain of metabolic enzymes by binding to their sulfhydryl group.52,54
FIG. 3. — Growth curves of E. coli in LB medium inoculated with 107 CFU of bacteria in the presence of different
concentrations of silver nanoparticles: (A) 0 lg cm3, () 10 lg cm3, (m) 50 lg cm3, and (&) 100 lg cm3.58
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2. AmmoniumCompounds. — Lately, bacterial infections have grown rapidly as a social health
problem.79 Thus, safe bactericidal technique plays a significant role in human health care.80 The
most common antibacterial agents mainly used in application nowadays are divided into four
groups81: oxidants, electrophilic agents, organic biocides, and cationic active biocides.
Chlorhexidine and quaternary ammonium compounds are categorized in the last division. These
compounds are mainly used in surfactants. Surfactants consist of two parts: a hydrocarbon region
that shows hydrophobic properties and a hydrophilic part that has a water-attracting tail. Quaternary
ammonium compounds (QACs) are classified as cationic agents. Along with their antibacterial
activity, QACs are outstanding for use in cleaning hard surfaces and for deodorization. QACs have
been classified as membrane-active agents for many years.82 As has been suggested by other
researchers,83 bacteria undergo a series of events when in contact with ammonium compound
cationic agents: (1) agents’ adhesion and insertion into the cell wall, (2) interaction with the
cytoplasmic membrane, (3) release of cytoplasmic material to the outer membrane space, (4) lysis
of proteins and nucleic acids, and (5) cell wall degradation via autolytic enzymes. Overall, loss and
damage of different parts of bacteria lead to bacteria death.84
V. CONCLUSION AND OUTLOOK
The microbial-contaminated glove is the most important cause of microbial transmission in
health care. Manufacturing antimicrobial gloves seems to be a possible solution for preventing
these contaminations. Because of microbial drug resistance, new effective antimicrobial drugs must
be developed. Different types of antimicrobial agents have been reviewed in this study, including
metal ions and antiseptic dyes. Great progress on nanoparticle-based antimicrobial gloves requires
consideration of the shared interest between microbiologists and nanoengineers in developing a
novel nanotechnology targeting a few major unmet challenges of antimicrobial agents.
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